Table 1.
Clinicopathologic characteristics of the discovery, validation and replication sets.
| SNUH | NCC | ||
|---|---|---|---|
| Total | Discovery set | Validation set | Replication set |
| (N = 4535) | (N = 1883) | (N = 1527) | (N = 1125) |
| Age, years (mean ± SD) | 63.2 ± 11.2 | 62.8 ± 11.4 | 61.3 ± 11.5 |
| Sex | |||
| Male | 1062 (56.4%) | 941 (61.6%) | 643 (57.2%) |
| Female | 821 (43.6%) | 586 (38.4%) | 482 (42.8%) |
| Body mass index, kg/m2 (mean ± SD) | 23.5 ± 3.3 | 23.1 ± 3.0 | 23.8 ± 3.1 |
| <30 kg/m2 | 1823 (96.8%) | 1494 (97.8%) | 1081 (97.3%) |
| ≥30 kg/m2 | 60 (3.2%) | 33 (2.2%) | 30 (2.7%) |
| Carcinoembryonic antigen | |||
| <5 μg/ml | 1414 (75.1%) | 1049 (68.7%) | 735 (65.6%) |
| ≥5 μg/ml | 469 (24.9%) | 478 (31.3%) | 385 (34.4%) |
| Tumour location | |||
| Proximal colon | 758 (40.3%) | 540 (35.4%) | 316 (28.1%) |
| Distal colon | 1115 (59.2%) | 964 (63.1%) | 785 (69.8%) |
| Mixed | 10 (0.5%) | 23 (1.5%) | 23 (2.1%) |
| Tumour stage | |||
| I | 264 (14.0%) | 194 (12.7%) | 201 (17.9%) |
| II | 624 (33.1%) | 493 (32.3%) | 331 (29.4%) |
| III | 643 (34.1%) | 501 (32.8%) | 493 (43.8%) |
| IV | 352 (18.7%) | 339 (22.2%) | 100 (8.9%) |
| Tumour grade | |||
| Low | 1732 (92.0%) | 1371 (89.8%) | 950 (90.5%) |
| High | 151 (8.0%) | 156 (10.2%) | 100 (9.5%) |
| Lymphovascular invasion | |||
| Absent | 1178 (62.6%) | 906 (59.3%) | 125 (11.8%) |
| Present | 705 (37.4%) | 621 (40.7%) | 931 (88.2%) |
| Adjuvant chemotherapy | |||
| No | 563 (29.9%) | 445 (29.1%) | 348 (36.98%) |
| Yes | 1320 (70.1%) | 1082 (70.9%) | 700 (63.1%) |
SD standard deviation, SNUH Seoul National University Hospital, NCC National Cancer Center Korea.